Alisertib (Synonyms: MLN 8237)

Name: Alisertib
Brand: MedChemExpress
SKU: HY-10971
Rating: 5.0 (72 reviews)

製品番号: HY-10971 純度: 99.36%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

Alisertib (MLN 8237) is an orally active and selective Aurora A kinase inhibitor (IC₅₀=1.2 nM), which binds to Aurora A kinase resulting in mitotic spindle abnormalities, mitotic accumulation. Alisertib (MLN 8237) induces apoptosis and autophagy through targeting the AKT/mTOR/AMPK/p38 pathway in leukemic cells. Antitumor activity.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 1028486-01-2

容量	価格（税別）	在庫状況	数量

>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 82	在庫あり	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 82	在庫あり	Estimated Time of Arrival: December 31
Solid
5 mg	$72	在庫あり	Estimated Time of Arrival: December 31
10 mg	$120	在庫あり	Estimated Time of Arrival: December 31
25 mg	$206	在庫あり	Estimated Time of Arrival: December 31
50 mg	$290	在庫あり	Estimated Time of Arrival: December 31
100 mg	$450	在庫あり	Estimated Time of Arrival: December 31
200 mg	$850	在庫あり	Estimated Time of Arrival: December 31
500 mg	$1200	在庫あり	Estimated Time of Arrival: December 31
1 g	$1620	在庫あり	Estimated Time of Arrival: December 31
5 g		お問い合わせ
10 g		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 72 publication(s) in Google Scholar

Other Forms of Alisertib:

Alisertib sodium お問い合わせ
Alisertib (Standard) お問い合わせ

顧客検証

IHC

: Alisertib purchased from MedChemExpress. Usage Cited in: FASEB J. 2018 May;32(5):2735-2746. [Abstract]; Representative immunofluorescence (IF) image and graph with frequency of ciliated WT or Pkd12/2 murine renal epithelial cells at 2 h after treatment with vehicle (V), Ganetespib (G), or Alisertib (A) to inhibit AURKA, or (C) combination of Alisertib and Ganetespib. On IF, acetylated a-tubulin (red); g-tubulin (green); DAPI (blue).

: Alisertib purchased from MedChemExpress. Usage Cited in: Drexel University. 2016 Nov.; Alisertib and combination treatment suppress proliferation in BT474 orthotopic tumors as shown by decrease in Ki-67, which is statistically significantly different between vehicle and combination treatment, FRAX1036 and Alisertib, and FRAX1036 and combination treatment.

: Alisertib purchased from MedChemExpress. Usage Cited in: Drexel University. 2016 Nov.; Alisertib enhances FRAX1036 inhibitory effect on PAK1 phosphorylation in BT474 xenograft model.

Aurora Kinase アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

Aurora Kinase Aurora A Aurora B Aurora C

生物活性
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

IC₅₀ & Target^[3]

Aurora A

1.2 nM (IC₅₀)

Aurora B

396.5 nM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
HCT-116	GI₅₀	0.03 μM Compound: 10, alisertib	Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation by BrdU incorporation assay	[PMID: 26101564]
HCT-116	IC₅₀	1.5 μM Compound: 10, alisertib	Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis Inhibition of aurora kinase B in human HCT116 cells assessed as inhibition of histone H3 phosphorylation by immunofluorescence analysis	[PMID: 26101564]
HCT-116	IC₅₀	32 μM Compound: MLN-8237	Antiproliferative activity against human HCT116 cells measured after 96 hrs by Brdu incorporation-based ELISA Antiproliferative activity against human HCT116 cells measured after 96 hrs by Brdu incorporation-based ELISA	[PMID: 31381325]
HCT-116	IC₅₀	7 nM Compound: 10, alisertib	Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis Inhibition of aurora kinase A autophosphorylation at T288 in human HCT116 cells by immunofluorescence analysis	[PMID: 26101564]
HCT-116	IC₅₀	95 nM Compound: 29, MLN-8237	Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay Antiproliferative activity against human HCT116 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HCT-15	IC₅₀	740 nM Compound: 29, MLN-8237	Antiproliferative activity against human HCT15 cells after 72 hrs by WST8 assay Antiproliferative activity against human HCT15 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HL-60	IC₅₀	74 nM Compound: 29, MLN-8237	Antiproliferative activity against human HL60 cells after 72 hrs by WST8 assay Antiproliferative activity against human HL60 cells after 72 hrs by WST8 assay	[PMID: 25625617]
HT-29	IC₅₀	330 nM Compound: 29, MLN-8237	Antiproliferative activity against human HT-29 cells after 72 hrs by WST8 assay Antiproliferative activity against human HT-29 cells after 72 hrs by WST8 assay	[PMID: 25625617]
LC-2-ad	IC₅₀	77 nM Compound: 29, MLN-8237	Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay Antiproliferative activity against human LC2/ad cells after 72 hrs by WST8 assay	[PMID: 25625617]
LU-99A	IC₅₀	62 nM Compound: 29, MLN-8237	Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay Antiproliferative activity against human LU99A cells after 72 hrs by WST8 assay	[PMID: 25625617]
MIA PaCa-2	IC₅₀	130 nM Compound: 29, MLN-8237	Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST8 assay Antiproliferative activity against human MIAPaCa2 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MKN-45	IC₅₀	93 nM Compound: 29, MLN-8237	Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay Antiproliferative activity against human MKN45 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MRC5	IC₅₀	> 10000 nM Compound: 29, MLN-8237	Antiproliferative activity against human MRC5 cells after 72 hrs by WST8 assay Antiproliferative activity against human MRC5 cells after 72 hrs by WST8 assay	[PMID: 25625617]
MV4-11	IC₅₀	1.2 nM Compound: 17	Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation of cells at G2/M phase measured after 12 hrs Induction of cell cycle arrest in human MV4-11 cells assessed as accumulation of cells at G2/M phase measured after 12 hrs	[PMID: 36306471]
NCI-H358	IC₅₀	100 nM Compound: 29, MLN-8237	Antiproliferative activity against human NCI-H358 cells after 72 hrs by WST8 assay Antiproliferative activity against human NCI-H358 cells after 72 hrs by WST8 assay	[PMID: 25625617]
PC-14	IC₅₀	170 nM Compound: 29, MLN-8237	Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay Antiproliferative activity against human PC14 cells after 72 hrs by WST8 assay	[PMID: 25625617]
Sf9	IC₅₀	1 nM Compound: 10, alisertib	Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATP Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATP	[PMID: 26101564]

体外実験

Alisertib (MLN 8237) leads the MM cells to mitotic spindle abnormalities, mitotic accumulation, as well as inhibition of cell proliferation through apoptosis and senescence. Alisertib up-regulates p53 and tumor suppressor genes p21 and p27^[1].
The decreased activity of Alisertib (MLN 8237) for the T217D/W277E Aurora A/TPX2 complex may reflect the increased affinity for ATP induced by cofactor binding to Aurora A^[2].
Alisertib (MLN 8237) inhibits cell proliferation with IC₅₀s ranging from 15 to 469 nM in different tumer cell lines^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Alisertib (MLN 8237) (30 mg/kg, p.o.) significantly reduces tumor burden and increases overall survival in xenograft-murine model of human-MM^[1].
Alisertib (3-30 mg/kg; p.o.; once daily for 3 weeks) causes tumor growth inhibition in solid tumor xenograft models^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Nude mice bearing HCT-116 colon tumor xenograft^[4]
Dosage:	3, 10, or 30 mg/kg
Administration:	P.o.; once daily for 3 weeks
Result:	Resulted in a dose-dependent TGI (tumor growth inhibition) of 43.3%, 84.2%, and 94.7% for the 3, 10, and 30 mg/kg groups,respectively.

臨床実験

分子量

518.92

分子式

C₂₇H₂₀ClFN₄O₄

CAS 番号

1028486-01-2

Appearance

Solid

Color

Off-white to yellow

SMILES

O=C(C1=CC=C(C=C1OC)NC2=NC=C3CN=C(C4=CC(Cl)=CC=C4C3=N2)C5=C(C=CC=C5F)OC)O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

溶剤 & 溶解度

体外:

DMSO : 25 mg/mL (48.18 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9271 mL	9.6354 mL	19.2708 mL
5 mM	0.3854 mL	1.9271 mL	3.8542 mL
10 mM	0.1927 mL	0.9635 mL	1.9271 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.08 mg/mL (4.01 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (19.27 mM); Suspended solution; Need ultrasonic
Protocol 2

Add each solvent one by one: 0.5% CMC-Na/saline water
Solubility: 5 mg/mL (9.64 mM); Suspended solution; Need ultrasonic
Protocol 3

Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 10 mg/mL (19.27 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 99.84%

Select Batch:

データシート (284 KB) SDS (393 KB)

COA (260 KB) HNMR (175 KB) LCMS (435 KB) Elemental Analysis Report (118 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Güllü G, et al. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood June 24, 2010 vol. 115 no. 25 5202-5213. [Content Brief]

[2]. Sloane DA, et al. Drug-Resistant Aurora A Mutants for Cellular Target Validation of the Small Molecule Kinase Inhibitors MLN8054 and MLN8237 ACS Chem. Biol., 2010, 5 (6), pp 563-576. [Content Brief]

[3]. Bavetsias V, et al. Aurora Kinase Inhibitors: Current Status and Outlook. Front Oncol. 2015 Dec 21;5:278. [Content Brief]

[4]. Manfredi MG, et al. Characterization of Alisertib (MLN8237), an investigational small-molecule inhibitor of aurora A kinase using novel in vivo pharmacodynamic assays.Clin Cancer Res. 2011 Dec 15;17(24):7614-7624. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9271 mL	9.6354 mL	19.2708 mL	48.1770 mL
	5 mM	0.3854 mL	1.9271 mL	3.8542 mL	9.6354 mL
	10 mM	0.1927 mL	0.9635 mL	1.9271 mL	4.8177 mL
	15 mM	0.1285 mL	0.6424 mL	1.2847 mL	3.2118 mL
	20 mM	0.0964 mL	0.4818 mL	0.9635 mL	2.4088 mL
	25 mM	0.0771 mL	0.3854 mL	0.7708 mL	1.9271 mL
	30 mM	0.0642 mL	0.3212 mL	0.6424 mL	1.6059 mL
	40 mM	0.0482 mL	0.2409 mL	0.4818 mL	1.2044 mL

Alisertib Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Alisertib1028486-01-2MLN 8237MLN8237MLN-8237Aurora KinaseAutophagyApoptosiscytotoxicitycell-cyclearrestmultiplemyelomamitoticspindlecancerInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

Alisertib (Synonyms: MLN 8237)

カスタマーレビュー

Other Forms of Alisertib:

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Aurora Kinase アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Alisertib Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

Alisertib (Synonyms: MLN 8237)

カスタマーレビュー

Other Forms of Alisertib:

Alisertib 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

Aurora Kinase アイソフォーム固有の製品をすべて表示:

生物活性

純度とドキュメンテーション

参考文献

カスタマーレビュー

Alisertib 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Alisertib Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report